Abstract:ABSTRACT Objective The gut microbiota (GM) can have complicated and often undetermined interactions with the function of many organs in the body. GM is altered in a variety of liver diseases, but the significance of such changes on the liver disease is still unclear. Hepatic autophagy deficiency causes liver injury accompanied with cholestasis. Here, we investigated the impact of such hepatic changes on GM and in turn the effect of gut dysbiosis on liver injury. Design Fecal microbiota from mice with liver-specific loss of autophagy-related gene 5 ( Atg5), Atg5 Δhep mice, were analyzed by 16S sequencing. Antibiotics (ABX) was used to modulate GM in mice. Cholestyramine was used to reduce the enterohepatic bile acid (BA) level. The functional role of fibroblast growth factor 15 (FGF15) and ileal farnesoid X receptor (FXR) was examined in mice over-expressing FGF15 gene, or given a fibroblast growth factor receptor 4 (FGFR4) inhibitor. Results The composition of GM was significantly changed with a notable increase of BA-metabolizing bacteria in Atg5 Δhep mice, leading to a lower proportion of tauro-conjugated BAs and a higher proportion of unconjugated BAs in the intestine, which markedly activated ileal FXR with an increased expression of FGF15. ABX or cholestyramine treatment exacerbated liver injury and ductular reaction, and decreased FGF15 expression, whereas modulating FGF15 signaling altered liver phenotypes in the autophagy-deficient mice. Conclusion Gut dysbiosis can remedy liver injury in Atg5 Δhep mice through the FXR-FGF15 signaling. Antibiotics use in the condition of liver injury may have unexpected adverse consequences via the gut-liver axis. SHORT SUMMARY What is already known about this subject? Gut microbiota (GM) can be altered during hepatic pathogenesis. GM are involved in bile acid (BA) metabolism. Autophagy deficiency in the liver disrupts BA homeostasis and causes cholestatic injury. What are the new findings? Deficiency of autophagy in the liver causes alteration of GM, which leads to a higher proportion of BA-metabolizing bacteria. GM contribute to the activation of ileal farnesoid X receptor (FXR) and a higher expression of fibroblast growth factor 15 (FGF15) in autophagy deficient condition in the liver, which is associated with decreased levels of conjugated BAs and increased levels of unconjugated BAs in the intestine. Manipulations that lead to GM alteration, intestinal BA signaling, or FGF15 signaling can all modulate the liver phenotype. BA and GM together can act as a sensor to liver injury to trigger FGF15-mediated protective mechanism. How might it impact on clinical practice in the foreseeable future? These findings indicate that gut dysbiosis in the scenario of liver disease can be beneficial, suggesting cautions should be exercised in the use of antibiotics during specific liver diseases. If antibiotics need to be used in patients with liver diseases it may be beneficial to enhance the FXR-FGF15 feedback signaling to retain the protective effect of GM.

Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling

Gut Pathobiont-Derived Outer Membrane Vesicles Drive Liver Inflammation and Fibrosis in Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease

Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis

Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis

Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis

Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis

Alterations in the Gut Microbiota and Serum Metabolomics of Spontaneous Cholestasis Caused by Loss of FXR Signal in Mice

Fecal deoxycholic acid associates with diet, intestinal microbes, and total bilirubin in primary sclerosing cholangitis

Cholangiocyte glycocalyx degradation boosts primary sclerosing cholangitis

Intestinal microbiota drives cholestasis-induced specific hepatic gene expression patterns

Gut Microbiota in Primary Sclerosing Cholangitis: From Prognostic Role to Therapeutic Implications

Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease

Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis

Gut microbiome in primary sclerosing cholangitis: A review

Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis

The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease

Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value

The microbiota and the gut–liver axis in primary sclerosing cholangitis

Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD

Gut dysbiosis protects against liver injury in autophagy deficient mice by FXR-FGF15 feedback signaling

Bile acid-gut microbiota imbalance in cholestasis and its long-term effect in mice